منابع مشابه
A rare adverse reaction of sorafenib
Sorafenib is a multikinase inhibitor thought to target vascular endothelial growth factor and its receptor. The European Medicines Agency (EAMA) and Food and Drug Administration (FDA) approved the use of sorafenib in late-stage hepatic cellular cancer (HCC) on October 30, 2007, and November 19, 2007, respectively. It is the only drug approved for use in the systematic treatment of primary HCC, ...
متن کاملPruritus, a rare but troublesome adverse reaction of topiramate
Case series report of presence of pruritus in five patients taking topiramate for treatment of epilepsy. This is a benign side effect of topiramate not previously reported that interfered with seizure treatment. Four out of five patients have previous history of antiepileptic drug (AED) allergy. Only one patient improved with a very slow titration, three of them discontinued treatment and one r...
متن کاملPatients' reaction to the disclosure of rare dreaded adverse events.
BACKGROUND Physicians must frequently inform their patients of the risks of rare, but serious, adverse events (AEs). OBJECTIVE To examine how patients react to the disclosure of rare AEs. METHODS Outpatients viewed a video of a physician describing a medication associated with a rare AE. Subjects then rated their worry, perceived chance of developing the AE, and willingness to take the medi...
متن کاملA rare type of reaction to tattoo materials: A granuloma annulare-like reaction
Granuloma annulare represents a reaction pattern that is recognized as idiopathic in many cases but is attributed to a variety of inciting factors in some cases. In this report, we present a case of granuloma annulare-like pattern reaction to tattoo pigment.
متن کامل[Palmoplantar cutaneous reaction to sorafenib].
Sorafenib is a new oral drug currently approved for the treatment of metastatic renal cell carcinoma and hepatocellular carcinoma. The drug acts partly by inhibiting the tyrosine kinase receptors implicated in angiogenesis and tumor progression, and partly by blocking Raf kinase pathways. Up to 90% of patients receiving this treatment are reported to develop dermatological sideeffects. Hyperker...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Libyan Journal of Medicine
سال: 2012
ISSN: 1993-2820,1819-6357
DOI: 10.3402/ljm.v7i0.19060